OBJECTIVE—Nonalcoholic fatty liver disease (NAFLD) is emerging as a major health problem in parallel with an increasing prevalence of obesity. Insulin resistance and abdominal and overall adiposity are closely associated with NAFLD; however, the interplay between them in the relationship with NAFLD is unclear, especially in nondiabetic individuals.

RESEARCH DESIGN AND METHODS—Abdominal ultrasound, hepatitis serology, and measurements of fasting plasma insulin (FPI), lipid concentrations, overall obesity (BMI), and abdominal obesity (waist circumference) were performed in 56,249 Korean subjects.

RESULTS—After rigorous exclusion criteria, 36,654 nondiabetic subjects (54% male) were enrolled. Subjects were divided into control (no fatty liver on ultrasound, serum alanine aminotransferase [ALT] <30 units/l [men] or <19 units/l [women]), fatty liver with normal ALT (FL-NALT), and fatty liver with a high ALT (FL-HALT) groups. After adjusting for age, BMI, and waist circumference, FPI and ratio of triglycerides to HDL cholesterol (TG/HDL-C ratio) were significantly higher in the FL-NALT than in the control group and even higher in the FL-HALT group. Odds ratios for the presence of FL-HALT with increasing quartiles of FPI and TG/HDL-C ratio were increased five- to sevenfold over those of the control group, independent of age, BMI, and waist circumference.

CONCLUSIONS—In this large population of individuals of Korean ancestry, results indicate that while overall (BMI) and abdominal (waist circumference) overweight/obesity are associated with features of NAFLD, surrogate estimates of insulin resistance, FPI concentration, and TG/HDL-C ratio predict NAFLD independently of age, BMI, and waist circumference.

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of disease, ranging from simple fatty liver or steatosis, a generally benign accumulation of triglyceride in hepatocytes, to nonalcoholic steatohepatitis, which can progress to chronic liver disease, cirrhosis, and hepatocellular carcinoma (1,2). Along with the “obesity epidemic,” the worldwide prevalence of NAFLD is increasing rapidly and is generally assumed to be a consequence of obesity-induced insulin resistance (13). On the other hand, not all obese individuals are insulin resistant, nor are all insulin-resistant individuals obese (46). Furthermore, many reports of the relationship between obesity, insulin resistance, and NAFLD have included relatively few individuals, often predominantly overweight and/or with some degree of glucose intolerance (79).

The current study was initiated to address some of these issues by taking advantage of a database of a large group of apparently healthy, nondiabetic, middle-aged subjects that included measurements of hepatic ultrasonography and serum hepatic transaminases. The primary goal of our analysis was to evaluate the relationship between NAFLD and two surrogate markers of insulin resistance taking into consideration the potentially confounding impact of differences in overall and abdominal obesity. The two surrogate markers of insulin resistance chosen for this purpose were fasting plasma insulin (FPI) concentration and plasma concentration ratio of triglycerides to HDL cholesterol (TG/HDL-C ratio). Both of these variables have been shown to be significantly correlated with a specific measure of insulin-mediated glucose uptake (10), with r values of ∼0.6.

The initial study population consisted of 56,249 subjects (33,546 men and 22,703 women) who volunteered for a health status evaluation in between 1 January and 30 September 2005 at Kangbuk Samsung Hospital, College of Medicine, Sungkyunkwan University. Data were obtained from a retrospective medical record review, and the study protocol was approved by the Kangbuk Samsung Hospital Ethics Committee. In addition to a complete medical history, physical examination, and chemical screening battery, all 56,249 subjects underwent an abdominal ultrasound and had blood drawn for serum levels of viral markers. To avoid confounding factors, the results of these preliminary observations resulted in the exclusion of a significant number from this analysis, based on: 1) a past history of diabetes or a fasting plasma glucose concentration >125 mg/dl (n = 2,630), 2) a history of malignancy (n = 293), 3) consumption of alcohol in amounts in excess of 70 g/week for women (n = 986) and 140 g/week for men (n = 8,688), or 4) hepatitis C antibody (HCV Ab) positivity (n = 107), hepatitis B surface antigen (HBsAg) positivity (n = 2,408), or solitary hepatitis B core antibody (HBcAb) positivity (n = 2,679). Also excluded from this analysis were subjects who took a variety of drugs reported to affect liver function (n = 376) and individuals with abnormal abdominal sonography results (evidence of malignancy, cirrhosis, or gall bladder disease) (n = 3,060). Thus, as some individuals met more than one exclusion criteria, the final number of subjects available for study was 36,654 (19,618 men and 17,036 women).

All subjects were seen after an overnight fast. Height and weight were determined, and BMI was expressed as weight (in kilograms) divided by the square of the height (in meters). Waist circumference was measured at the midlevel between the lowest rib and the iliac crest with the subject standing and breathing normally. Blood samples were collected, plasma separated, and alanine aminotransferase (ALT) measured by ultraviolet without P5P method (Advia 1650 Autoanalyzer; Byer Diagnostics, Leverkusen, Germany). HBsAg and HBsAb were measured by chemiluminescent microparticle immunoassay (Architect i2000 SR; Abbott, Abbott Park, IL). HBcAb immunoglobulin G was measured by radioimmunoassay (Titertek, AL). HCV Ab was measured by polymerase chain reaction (Cobas Amplicor; Roche, Basel, Switzerland). Insulin concentrations were determined by immunoradiometric assay (Biosource, Nivelles, Belgium), with intra- and interassay CVs of 2.1–4.5 and 4.7–12.2%, respectively. An enzymatic colorimetric test was used to measure total cholesterol and triglyceride concentrations (Hitachi 912 analyzer; Roche Diagnostics). The selective inhibition method was used to measure the level of HDL cholesterol, and a homogeneous enzymatic colorimetric test was used to measure the level of LDL cholesterol (Advia 1650 Autoanalyzer; Byer Diagnostics).

Abdominal ultrasonography (Aspen, Acuson, PA) was performed to detect the presence of fatty infiltration in the liver by a core laboratory of experienced radiologists, all of whom used standard criteria in evaluating the images for hepatic fat (11). The severity of the fatty liver was classified into three groups, grades 1–3, according to the Mittelstaedt classification (11). Subjects with both fatty liver and an ALT of <30 units/l for men and <19 units/l for women, as described by Prati et al. (12), were classified as having fatty liver with a normal ALT (FL-NALT). Patients with fatty liver and a serum ALT >30 units/l for men and >19 units/l for women were classified as having fatty liver with a high ALT (FL-HALT). These ALT cut points were determined after a review of previous work both in Koreans (13,14) and non-Koreans (12,15) in an effort to use sex-specific cut points that accurately detected abnormal values. Finally, subjects without fatty liver on ultrasound but an ALT >30 units/l for men or >19 units/l for women (n = 5,414 subjects) were not included in this analysis, but the mean FPI and TG/HDL-C ratio concentrations for this group were compared with the other groups and are presented.

Since specific measures of insulin-mediated glucose uptake had not been performed, the two following surrogate estimates of insulin sensitivity were used to assess the relationship between insulin resistance/hyperinsulinemia and fatty liver. FPI concentrations are significantly correlated with direct measures of insulin resistance (10,16). The plasma concentration of TG/HDL-C ratio is as closely related to direct measures of insulin resistance as FPI concentration (10) but has been shown to be superior to both triglycerides and HDL cholesterol alone (17).

Statistics

Statistical analysis of the data were performed using SPSS version 14.0 (SPSS, Point Richmond, CA), and the continuous variable data are presented as means ± SD. Student's unpaired t test was used to compare the means of grade 1 fatty liver versus grades 2 and 3 combined. ANOVA was used to evaluate the overall differences in means. ANCOVA was used to assess the effect of weight (BMI and waist circumference) on the relationship between markers of insulin resistance and the presence of fatty liver. For the comparison of nominal variables, the χ2 method was used for cross-tabulation analysis. Multiple logistic regression analysis was used to analyze relationships between age, BMI, waist circumference, and insulin and the TG/HDL-C ratio and the presence of FL-NALT and FL-HALT. P values <0.05 were considered to be statistically significant.

Overall, the 36,654 subjects were relatively young (mean ± SD age 41 ± 9 years [men 41 ± 8, women 41 ± 9]) and nonobese (BMI 23.0 ± 3.0 kg/m2 [men 24.3 ± 2.8, women 22.2 ± 2.9] and waist circumference 78 ± 9 cm [men 83 ± 8, women 72 ± 8]). Hepatic ultrasonography indicated that 27,632 subjects were without evidence of fatty liver (75.4%), while the remaining subjects had grade 1 (21.4%, 6,149 men, 1,683 women), grade 2 (3.2%, 977 men, 181 women), or grade 3 (0.09%, 29 men, 3 women) fatty liver. In Table 1, the subjects are separated by fatty liver grade and sex. Subjects with grades 2 and 3 were combined into one category due to the very small numbers in grade 3. For the remainder of the presented analyses the fatty liver grades are not separated, and the data are presented for two groups: FL-NALT and FL-HALT.

The presence of fatty liver and elevation of ALT increased with the degree of both overall and abdominal obesity

The relevant clinical characteristics of the 36,654 subjects, divided into the three experimental groups (control, FL-NALT, and FL-HALT) are shown in Table 1, with the two fatty liver groups also divided into fatty liver grades. In general, the fatty liver groups had a higher overall (BMI) and abdominal (waist circumference) obesity than the control group, and the FL-HALT group was significantly more obese by both measures than the FL-NALT group. These data also show a significant trend of worsening metabolic variables (FPI, triglyceride, and HDL cholesterol concentrations and TG/HDL-C ratio) across the groups from the control to the FL-NALT and FL-HALT groups. After division of the two fatty liver groups into grades of fatty liver, the same can be said of men with grade 2 fatty liver in comparison with those with grade 1 fatty liver, within both the FL-NALT and the FL-HALT groups. Thus, in men, the degree of steatosis was positively associated with worsening metabolic variables. For women, although the division into grades of fatty liver also demonstrated an association between worsening metabolic variables and a higher grade of fatty liver, women with grade 2/3 fatty liver in the two fatty liver/ALT groups had equivalent mean values for variables.

Table 2 presents the mean values for FPI concentration and the TG/HDL-C ratio of the three experimental groups this time adjusted for differences in age, BMI, and waist circumference. These results indicate that the estimates of insulin resistance increased in magnitude in parallel with presence of fatty liver and increased ALT level, with each group being significantly different from the other two groups.

Odds ratios for features of NAFLD increased with increasing insulin resistance, independently of obesity

To quantify the adverse impact of obesity on the degree of liver disease, odds ratios (ORs) were calculated between age, BMI, and waist circumference and the presence of FL-NALT or FL-HALT (Table 3). For men, in this relatively young population, being older did not seem to have an adverse effect on the presence of NAFLD. However, in women, the two fatty liver groups were significantly older than the control subjects. In terms of adiposity, the larger the BMI or waist circumference, the greater the OR of having either FL-NALT or FL-HALT. The increase in ORs ranged from 10 to 30%, with the values for BMI and waist circumference of seemingly comparable magnitude.

As shown in Table 4, the impact of insulin resistance was assessed with the calculation of ORs between FPI and TG/HDL-C ratio concentrations and the presence of FL-NALT or FL-HALT. For this purpose, the experimental population was divided into quartiles on the basis of their FPI concentration or their TG/HDL-C ratio. Age, BMI, and waist circumference were included in the regression model for both the FPI and TG/HDL-C ratio analyses, so that the increasing quartiles of the two markers of insulin resistance are independent of these three variables. In terms of FPI concentration, when comparing each of the three highest insulin quartiles with the lowest, ORs for the presence of FL-HALT increased significantly in both men and women, with the OR increasing five- to sixfold in the quartile with the highest FPI concentration. Similar results are seen for TG/HDL-C ratio. When examining the ORs for FPI and TG/HDL-C ratio concentrations in predicting the presence of FL-NALT, the results are similar for women, albeit of smaller magnitude. However, for men, the OR for FL-NALT decreased with the highest FPI quartile, indicating a decrease in risk with this degree of hyperinsulinemia. This is difficult to explain but could indicate that in men an increasing FPI concentration is less associated with steatosis alone and more associated with steatohepatitis. This is with the caveat that ALT is only a moderately accurate marker of inflammatory activity. Thus, apart from this one exception, the higher the FPI and TG/HDL-C ratio concentrations, the significantly greater the OR of having either FL-NALT or FL-HALT.

Secondary analyses

A total of 5,414 subjects (3,412 women, 2,002 men) with an isolated elevated ALT (>30 units/l for men and >19 units/l for women), i.e., no fatty liver on ultrasound, were excluded from the above analyses. We compared the mean FPI and TG/HDL-C ratio concentrations for this group with those of our other groups and found that for both of these measures the mean values for the isolated ALT group were significantly lower than those in either the FL-NALT or the FL-HALT groups after adjusting for age, BMI, and waist circumference (data not shown).

Both obesity and insulin resistance have been identified as factors associated with deposition of fat in the liver, although it is unclear whether they are a cause of hepatic fat (1821) or a result of hepatic fat (2225). Because obesity and insulin resistance are themselves significantly correlated (26,27), it is difficult to clarify which of these two variables is most closely related to increased hepatic fat content. The problem is further confounded by questions as to the relative adverse impact of overall obesity as compared with abdominal obesity. This study is, to the best of our knowledge, the largest that has been performed in analyzing associations between measures of overall and abdominal obesity, insulin resistance, hepatic transaminases, and fatty liver, using a comprehensive evaluation including ultrasound, hepatic enzymes, and serum viral markers, in a nondiabetic apparently healthy population.

Based on the results in Tables 1 and 2, it appears that both surrogate estimates of insulin resistance used in this study (FPI and TG/HDL-C ratio concentrations) are independently associated with severity of liver disease. Thus, although the results in Table 1 indicate that both estimates of obesity (BMI and waist circumference) and the two surrogate estimates of insulin resistance all increased significantly as a function of the presence of steatosis and a raised ALT, it can be seen from Table 2 that FPI and TG/HDL-C ratio concentrations continued to be statistically associated with these features of liver disease when adjusted for differences in age, BMI, and waist circumference. Furthermore, when the subjects were divided into quartiles based on magnitude of surrogate estimates of insulin resistance, the OR of having evidence of FL-HALT increased significantly with each successively higher quartile (Table 4). As in the results in Table 2, these findings were independent of differences in age, BMI, and waist circumference and, with the exception of relatively minor quantitative differences, were true of both sexes. Thus, in answer to the question we posed, the evidence strongly supports the notion that although both overall and abdominal obesity are associated with fatty liver, the specific relationship between insulin resistance and fatty liver is independent of either overall or abdominal obesity.

It is of interest that the relationships between either index of obesity and hepatic fat content were quite comparable, so that neither waist circumference nor BMI was more predictive of hepatic fat than the other. However, the population under study was a very specific population of East Asian ancestry, with a lower mean BMI and waist circumference than seen in Caucasians, and these findings may not be applicable to other ethnic groups. Further, it should be emphasized that the specific cut points that performed the best in this analysis may only be applicable to individuals of Korean ethnicity.

Although the results of this study seem relatively straight forward, certain weaknesses should be acknowledged. First, subjects with sonographic evidence of cirrhosis were excluded, and in doing so some NAFLD chronic liver disease or cirrhosis may have also been excluded, explaining why we found such small numbers with grade 3 fatty liver. Second, NAFLD cirrhosis, where the hepatic fat tends to be greatly diminished, can be mistaken sonographically for normal nonfatty liver (28). Third, and most importantly, our conclusions are based on the combined use of hepatic ultrasonography and ALT measurements as markers of NAFLD, without morphological examination of hepatic tissue. We used “FL-HALT” to attempt to measure prevalence of inflammatory activity in the liver, to distinguish this from benign fatty liver. We acknowledge that serum ALT levels have been shown to be at best a moderate predictor of hepatic necroinflammatory damage or steatohepatitis (2931); however, we would argue that the large number of apparently healthy individuals studied precludes the possibility of obtaining histology.

In summary, we demonstrate that although both adiposity and surrogate estimates of insulin resistance (FPI and TG/HDL-C ratio concentrations) are associated with the estimates of NAFLD in this healthy nondiabetic Korean population, these measures of insulin resistance predict NAFLD independently of both overall and abdominal overweight/obesity.

Table 1—

Clinical characteristics of the control group and the two fatty liver groups divided by grade of fatty liver and sex

Men (n = 17,616)
Women (n = 13,624)
ControlFL-NALT
FL-HALT
P overallControlFL-NALT
FL-HALT
P overall
Grade 1Grade 2/3P*Grade 1Grade 2/3P*Grade 1Grade 2/3P*Grade 1Grade 2/3P*
n 10,461 2,815 128  3,334 878   11,757 695 21  988 163   
Age (years) 40 ± 8 42 ± 8 40 ± 9 0.08 40 ± 7 39 ± 7 <0.01 <0.01 39 ± 8 45 ± 10 46 ± 12 0.85 49 ± 11 47 ± 11 0.14 <0.01 
BMI (kg/m222.9 ± 2.4 25.2 ± 2.2 26.9 ± 2.5 <0.01 26.1 ± 2.3 27.5 ± 2.6 <0.01 <0.01 21.6 ± 2.4 25.0 ± 2.8 28.6 ± 5.2 <0.05 25.6 ± 2.8 28.3 ± 3.3 <0.01 <0.01 
Waist circumference (cm) 79 ± 7 86 ± 6 90 ± 8 <0.01 88 ± 6 92 ± 7 <0.01 <0.01 71 ± 7 80 ± 7 96 ± 14 <0.01 82 ± 7 88 ± 8 <0.01 <0.01 
FPI (pmol/l) 45 ± 15 56 ± 18 65 ± 22 <0.01 65 ± 23 77 ± 39 <0.01 <0.01 47 ± 17 62 ± 22 77 ± 25 <0.02 70 ± 25 73 ± 26 0.03 <0.01 
Triglycerides (mmol/l) 1.3 ± 0.7 1.9 ± 1.0 2.2 ± 1.2 <0.01 2.1 ± 1.1 2.4 ± 1.3 <0.01 <0.01 1.0 ± 0.5 1.6 ± 1.0 2.3 ± 1.5 <0.01 1.8 ± 1.0 2.1 ± 1.3 <0.01 <0.01 
HDL cholesterol (mmol/l) 1.3 ± 0.3 1.2 ± 0.2 1.1 ± 0.2 <0.01 1.2 ± 0.2 1.1 ± 1.8 <0.01 <0.01 1.5 ± 0.3 1.3 ± 0.3 1.2 ± 0.3 0.02 1.3 ± 0.3 1.3 ± 0.2 <0.01 <0.01 
TG/HDL-C ratio (mmol/l) 1.0 ± 0.5 1.6 ± 0.4 2.0 ± 0.8 <0.01 1.8 ± 0.6 2.2 ± 1.4 <0.01 <0.01 0.7 ± 0.4 1.2 ± 0.5 1.9 ± 0.7 0.02 1.4 ± 0.5 1.6 ± 0.6 <0.01 <0.01 
Men (n = 17,616)
Women (n = 13,624)
ControlFL-NALT
FL-HALT
P overallControlFL-NALT
FL-HALT
P overall
Grade 1Grade 2/3P*Grade 1Grade 2/3P*Grade 1Grade 2/3P*Grade 1Grade 2/3P*
n 10,461 2,815 128  3,334 878   11,757 695 21  988 163   
Age (years) 40 ± 8 42 ± 8 40 ± 9 0.08 40 ± 7 39 ± 7 <0.01 <0.01 39 ± 8 45 ± 10 46 ± 12 0.85 49 ± 11 47 ± 11 0.14 <0.01 
BMI (kg/m222.9 ± 2.4 25.2 ± 2.2 26.9 ± 2.5 <0.01 26.1 ± 2.3 27.5 ± 2.6 <0.01 <0.01 21.6 ± 2.4 25.0 ± 2.8 28.6 ± 5.2 <0.05 25.6 ± 2.8 28.3 ± 3.3 <0.01 <0.01 
Waist circumference (cm) 79 ± 7 86 ± 6 90 ± 8 <0.01 88 ± 6 92 ± 7 <0.01 <0.01 71 ± 7 80 ± 7 96 ± 14 <0.01 82 ± 7 88 ± 8 <0.01 <0.01 
FPI (pmol/l) 45 ± 15 56 ± 18 65 ± 22 <0.01 65 ± 23 77 ± 39 <0.01 <0.01 47 ± 17 62 ± 22 77 ± 25 <0.02 70 ± 25 73 ± 26 0.03 <0.01 
Triglycerides (mmol/l) 1.3 ± 0.7 1.9 ± 1.0 2.2 ± 1.2 <0.01 2.1 ± 1.1 2.4 ± 1.3 <0.01 <0.01 1.0 ± 0.5 1.6 ± 1.0 2.3 ± 1.5 <0.01 1.8 ± 1.0 2.1 ± 1.3 <0.01 <0.01 
HDL cholesterol (mmol/l) 1.3 ± 0.3 1.2 ± 0.2 1.1 ± 0.2 <0.01 1.2 ± 0.2 1.1 ± 1.8 <0.01 <0.01 1.5 ± 0.3 1.3 ± 0.3 1.2 ± 0.3 0.02 1.3 ± 0.3 1.3 ± 0.2 <0.01 <0.01 
TG/HDL-C ratio (mmol/l) 1.0 ± 0.5 1.6 ± 0.4 2.0 ± 0.8 <0.01 1.8 ± 0.6 2.2 ± 1.4 <0.01 <0.01 0.7 ± 0.4 1.2 ± 0.5 1.9 ± 0.7 0.02 1.4 ± 0.5 1.6 ± 0.6 <0.01 <0.01 

Data are means ± SD.

*

Comparison between grades 1 and 2 fatty liver (unpaired student's t test); P overall = ANOVA including the FL-NALT, FL-HALT (without dividing by grade of fatty liver), and control groups. FL-NALT: steatosis detected on ultrasound with ALT <30 units/l (men) or <19 units/l (women); FL-HALT: steatosis detected on ultrasound with ALT >30 units/l (men) or >19 units/l (women).

Table 2—

Mean ± SD values for FPI and TG/HDL-C ratio concentrations adjusted for differences in age, BMI, and waist circumference in the three groups (control, FL-NALT, and FL-HALT) divided by sex (ANCOVA)

ControlFL-NALTFL-HALTMultiple comparison
Men (N = 17,616)     
    n 10,461 2,943 4,212  
    FPI (pmol/l) 49 ± 16 55 ± 18 62 ± 27 1≠2, 1≠3, 2≠3 
    TG/HDL-C ratio (mmol/l) 1.2 ± 0.7 1.6 ± 1.1 1.8 ± 2.2 1≠2, 1≠3, 2≠3 
Women (N = 16,483)     
    n 11,757 716 1,151  
    FPI (pmol/l) 50 ± 17 60 ± 22 68 ± 25 1≠2, 1≠3, 2≠3 
    TG/HDL-C ratio (mmol/l) 0.7 ± 0.5 1.1 ± 0.9 1.2 ± 0.9 1≠2, 1≠3, 2≠3 
ControlFL-NALTFL-HALTMultiple comparison
Men (N = 17,616)     
    n 10,461 2,943 4,212  
    FPI (pmol/l) 49 ± 16 55 ± 18 62 ± 27 1≠2, 1≠3, 2≠3 
    TG/HDL-C ratio (mmol/l) 1.2 ± 0.7 1.6 ± 1.1 1.8 ± 2.2 1≠2, 1≠3, 2≠3 
Women (N = 16,483)     
    n 11,757 716 1,151  
    FPI (pmol/l) 50 ± 17 60 ± 22 68 ± 25 1≠2, 1≠3, 2≠3 
    TG/HDL-C ratio (mmol/l) 0.7 ± 0.5 1.1 ± 0.9 1.2 ± 0.9 1≠2, 1≠3, 2≠3 

FL-NALT: steatosis detected on ultrasound with ALT <30 units/l (men) or <19 units/l (women); FL-HALT: steatosis detected on ultrasound with ALT >30 units/l (men) or >19 units/l (women). ≠, two groups are different.

Table 3—

Age, BMI, and waist circumference ORs and 95% CIs for risk of sonographic liver fat and elevated ALT level in men and women

FL-NALT
FL-HALT
OR95% CIPOR95% CIP
Men       
    Age 1.02 1.01–1.02 0.001 0.97 0.96–0.98 <0.001 
    BMI 1.12 1.08–1.16 <0.001 1.26 1.22–1.31 <0.001 
    Waist circumference 1.03 1.01–1.04 <0.001 1.11 1.09–1.12 <0.001 
Women       
    Age 1.02 1.00–1.03 0.007 1.05 1.04–1.09 <0.001 
    BMI 1.20 1.11–1.24 <0.001 1.29 1.23–1.36 <0.001 
    Waist circumference 1.06 1.03–1.08 <0.001 1.06 1.04–1.09 <0.001 
FL-NALT
FL-HALT
OR95% CIPOR95% CIP
Men       
    Age 1.02 1.01–1.02 0.001 0.97 0.96–0.98 <0.001 
    BMI 1.12 1.08–1.16 <0.001 1.26 1.22–1.31 <0.001 
    Waist circumference 1.03 1.01–1.04 <0.001 1.11 1.09–1.12 <0.001 
Women       
    Age 1.02 1.00–1.03 0.007 1.05 1.04–1.09 <0.001 
    BMI 1.20 1.11–1.24 <0.001 1.29 1.23–1.36 <0.001 
    Waist circumference 1.06 1.03–1.08 <0.001 1.06 1.04–1.09 <0.001 

FL-NALT: steatosis detected on ultrasound with ALT <30 units/l (men) or <19 units/l (women); FL-HALT: steatosis detected on ultrasound with ALT >30 units/l (men) or >19 units/l (women).

Table 4—

ORs and 95% CIs for risk of sonographic liver fat with and without an elevated serum ALT, with increasing FPI and TG/HDL-C ratio concentration quartiles, independent of age, BMI, and waist circumference for men and women

FL-NALT
FL-HALT
OR95% CIPOR95% CIP
Men       
    FPI quartiles (mmol/l)       
I (12.6∼37.2)     
II (37.3∼48.6) 1.70 1.41–2.04 <0.001 1.89 1.51–2.36 <0.001 
III (48.7∼62.4) 2.84 1.97–3.82 <0.001 2.80 2.26–3.47 <0.001 
IV (62.58∼804.0) 1.79 1.48–2.16 <0.001 6.25 5.07–7.70 <0.001 
    TG/HDL-C ratio quartiles (mmol/l)       
I ( 0.19∼0.77)     
II (1.77∼1.14) 1.92 1.59–2.32 <0.001 2.06 1.63–2.52 <0.001 
III (1.15∼1.73) 2.36 1.97–2.84 <0.001 3.27 2.66–4.02 <0.001 
IV (1.74∼13.3) 2.73 2.27–3.29 <0.001 5.88 4.80–7.21 <0.001 
Women       
    FPI quartiles (mmol/l)       
I (12.0∼37.8)     
II (37.9∼47.4) 1.78 1.16–2.73 0.008 1.24 0.80–1.91 0.339 
III (47.5∼60.6) 2.29 1.53–3.43 <0.001 2.23 1.53–3.36 <0.001 
IV (60.7∼495.6) 2.89 1.95–4.28 <0.001 6.40 4.42–9.25 <0.001 
    TG/HDL-C ratio quartiles (mmol/l)       
I (0.12∼0.44)     
II (0.45∼0.63) 2.68 1.54–4.66 <0.001 1.36 0.85–2.19 0.205 
IIII (0.64∼0.95) 5.13 3.05–8.61 <0.001 2.62 1.71–4.01 <0.001 
IV (0.96∼23.5) 7.66 4.59–12.77 <0.001 6.65 4.43–9.98 <0.001 
FL-NALT
FL-HALT
OR95% CIPOR95% CIP
Men       
    FPI quartiles (mmol/l)       
I (12.6∼37.2)     
II (37.3∼48.6) 1.70 1.41–2.04 <0.001 1.89 1.51–2.36 <0.001 
III (48.7∼62.4) 2.84 1.97–3.82 <0.001 2.80 2.26–3.47 <0.001 
IV (62.58∼804.0) 1.79 1.48–2.16 <0.001 6.25 5.07–7.70 <0.001 
    TG/HDL-C ratio quartiles (mmol/l)       
I ( 0.19∼0.77)     
II (1.77∼1.14) 1.92 1.59–2.32 <0.001 2.06 1.63–2.52 <0.001 
III (1.15∼1.73) 2.36 1.97–2.84 <0.001 3.27 2.66–4.02 <0.001 
IV (1.74∼13.3) 2.73 2.27–3.29 <0.001 5.88 4.80–7.21 <0.001 
Women       
    FPI quartiles (mmol/l)       
I (12.0∼37.8)     
II (37.9∼47.4) 1.78 1.16–2.73 0.008 1.24 0.80–1.91 0.339 
III (47.5∼60.6) 2.29 1.53–3.43 <0.001 2.23 1.53–3.36 <0.001 
IV (60.7∼495.6) 2.89 1.95–4.28 <0.001 6.40 4.42–9.25 <0.001 
    TG/HDL-C ratio quartiles (mmol/l)       
I (0.12∼0.44)     
II (0.45∼0.63) 2.68 1.54–4.66 <0.001 1.36 0.85–2.19 0.205 
IIII (0.64∼0.95) 5.13 3.05–8.61 <0.001 2.62 1.71–4.01 <0.001 
IV (0.96∼23.5) 7.66 4.59–12.77 <0.001 6.65 4.43–9.98 <0.001 

FL-NALT: steatosis detected on ultrasound with ALT <30 units/l (men) or <19 units/l (women); FL-HALT: steatosis detected on ultrasound with ALT >30 units/l (men) or >19 units/l (women).

We acknowledge the efforts of the health screening group at Kangbuk Samsung Hospital, Seoul, South Korea.

1.
Angulo P: Nonalcoholic fatty liver disease.
N Engl J Med
346
:
1221
–1231, 2002
2.
Clark JM, Brancati FL, Diehl AM: Nonalcoholic fatty liver disease.
Gastroenterology
122
:
1649
–1657,
2002
3.
McCullough AJ: Pathophysiology of nonalcoholic steatohepatitis (Review).
J Clin Gastroenterol
40(Suppl. 1)
:
S17
–S29,
2006
4.
Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G: Insulin resistance and hypersecretion in obesity: European Group for the Study of Insulin Resistance (EGIR).
J Clin Invest
100
:
1166
–1173,
1997
5.
Abbasi F, Brown BW Jr, Lamendola C, McLaughlin T, Reaven GM: Relationship between obesity, insulin resistance, and coronary heart disease risk.
J Am Coll Cardiol
40
:
937
–943,
2002
6.
Jones CN, Abbasi F, Carantoni M, Polonsky KS, Reaven GM: Roles of insulin resistance and obesity in regulation of plasma insulin concentrations.
Am J Physiol Endocrinol Metab
278
:
E501
—E508, 2000
7.
Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N: Association of nonalcoholic fatty liver disease with insulin resistance.
Am J Med
107
:
450
–455,
1999
8.
Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J: NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome.
Hepatology
35
:
373
–379,
2002
9.
Tiikkainen M, Tamminen M, Häkkinen AM, Bergholm R, Vehkavaara S, Halavaara J, Teramo K, Rissanen A, Yki-Järvinen H: Liver fat accumulation and insulin resistance in obese women with previous GDM.
Obes Res
10
:
859
–867,
2002
10.
McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven GM: Use of metabolic markers to identify individuals who are insulin resistant.
Ann Intern Med
139
:
802
–809,
2003
11.
Mittelstaedt CA, Vincent LM:
Abdominal Ultrasound
. New York, Churchill Livingston,
1987
12.
Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G: Updated definitions of healthy ranges for serum alanine aminotransferase levels.
Ann Intern Med
137
:
1
–10,
2002
13.
Kim HC, Choi KS, Jang YH, Shin HW, Kim DJ: Normal serum aminotransferase levels and the metabolic syndrome: Korean National Health and Nutrition Examination Surveys.
Yonsei Med J
47
:
542
–550,
2006
14.
Park HS, Han JH, Choi KM, Kim SM: Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents.
Am J Clin Nutr
82
:
1046
–1051,
2005
15.
Clark JM, Diehl AM: Defining nonalcoholic fatty liver disease: implications for epidemiologic studies.
Gastroenterology
124
:
248
–250,
2003
16.
Lee S, Choi S, Kim HJ, Chung YS, Lee KW, Lee HC, Huh KB, Kim DJ: Cutoff values of surrogate measures of insulin resistance for metabolic syndrome in Korean non-diabetic adults.
J Korean Med Sci
21
:
695
–700,
2006
17.
McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, Simon J, Krauss RM: Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?
Am J Cardiol
96
:
399
–404,
2005
18.
Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.
Hepatology
37
:
917
–923,
2003
19.
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.
Diabetes
50
:
1844
–1850,
2001
20.
Haukeland JW, Konopski Z, Linnestad P, Azimy S, Marit Løberg E, Haaland T, Birkeland K, Bjøro K: Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease.
Scand J Gastroenterol
40
:
1469
–1477,
2005
21.
Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG: Liver pathology and the metabolic syndrome X in severe obesity.
J Clin Endocrinol Metab
84
:
1513
–1517,
1999
22.
Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, Goto T, Westerbacka J, Sovijärvi A, Halavaara J, Yki-Järvinen H: Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men.
J Clin Endocrinol Metab
87
:
3023
–3028,
2002
23.
Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance.
J Clin Invest
116
:
1793
–1801,
2006
24.
Arkan MC, Havener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M: IKK-beta links inflammation to obesity-induced insulin resistance.
Nat Med
11
:
191
–198,
2005
25.
Boden G, She P, Mozzoli M, Cheung P, Gumireddy K, Reddy P, Xiang X, Luo Z, Ruderman N: Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kB pathway in rat liver.
Diabetes
54
:
3458
–3465,
2005
26.
Kim SH, Abbasi F, Reaven GM: Impact of degree of obesity on surrogate estimates of insulin resistance.
Diabetes Care
27
:
1998
–2002,
2004
27.
Farin HM, Abbasi F, Reaven GM: Body mass index and waist circumference both contribute to differences in insulin-mediated glucose disposal in nondiabetic adults.
Am J Clin Nutr
83
:
47
–51,
2006
28.
Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ: The utility of radiological imaging in nonalcoholic fatty liver disease.
Gastroenterology
123
:
745
–750,
2002
29.
Dixon JB, Bhathal PS, O'Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.
Gastroenterology
121
:
91
–100,
2001
30.
Amarapurka DN, Amarapurkar AD, Patel ND, Agal S, Baigal R, Gupte P, Pramanik S: Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis.
Ann Hepatol
5
:
30
–33,
2006
31.
Palekar NA, Naus R, Larson SP, Ward J, Harrison SA: Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.
Liver Int
26
:
151
–156,
2006

Published ahead of print at http://care.diabetesjournals.org on 7 May 2007. DOI: 10.2337/dc07-0512.

K.C.S. and M.C.R. contributed equally to this article.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.